Screening and Treatment for Lung Cancer: What's Next?

The second part of the webinar Lung Cancer Screening and Treatment: What's Next? focuses on the review of lung cancer screening and treatment status amid the COVID-19 pandemic. Participating faculty include Albert Rizzo, MD, FCCP, FACP, FAASM; James L. Mulshine, MD; Andrea Borondy Kitts, MS, MPH; and Sandip Patel, MD.

James L. Mulshine, MD, professor of internal medicine, and associate director of Institute of Translation Medicine at Rush University, discusses the benefits of establishing a timely and investigation-informed screening and referral practice for patients who are at risk for developing lung cancer.

Sandip Patel, MD, an associate professor of medical oncology at University of California San Diego, explains the optimal diagnostic strategies that can be utilized to better inform biomarker-based therapies in lung cancer.

Jacob Sands, MD, a physician at Dana-Farber Cancer Institute, as well as an instructor of medicine at Harvard Medical School, describes the last decade in lung cancer diagnostics and significant therapeutic advances. He also navigates the emerging classes of drugs that are beginning to make headway in the lung cancer pipeline.

Andrea Borondy Kitts, a lung cancer and patient advocate at Rescue Lung Society, educates physicians on adequate physician-to-patient education and resources that improve their opportunity for success in lung cancer care.

M. Patricia Rivera, MD, a professor of medicine at The University of North Carolina at Chapel Hill, reviews the United States Preventive Services Task Force's lung cancer screening recommendations as of 2021, including the impacted patient populations and effect the recommendations have on direct physician care.